Liste modèle des médicaments essentiels

Abiraterone

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Anastrozole

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 1 mg tablet	Malignant neoplasms of breast Other specified malignant neoplasms of breast

Bicalutamide

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 50 mg	Malignant neoplasms of prostate

Dexamethasone

Section	Indications
Hormones and antihormones ◦ Oral > Liquid: 2 mg per 5 mL ◦ Oral > Solid: 2 mg; 4 mg ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt) ◦ Oral > Liquid: 2 mg per 5 mL (as sodium phosphate) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) ◦ Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base) ◦ Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base ◦ Oral > Solid > tablet: 4 mg (as dexamethasone base)	Anaplastic large cell lymphoma, ALK-negative Lymphoid leukaemia, not elsewhere classified Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-positive

Enzalutamide

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 40 mg	Therapeutic equivalent to abiraterone pour Malignant neoplasms of prostate Malignant neoplasms of prostate

Flutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate

Fulvestrant

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IV: 250 mg per 5 mL	Malignant neoplasms of breast

Goserelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate

Hydrocortisone

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)	Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Unspecified malignant neoplasms of unspecified sites

Leuprorelin

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe	Malignant neoplasms of breast Malignant neoplasms of prostate

Methylprednisolone

Section	Indications
Hormones and antihormones ◦ Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate) ◦ Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection	Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified

Nilutamide

Section	Indications
Hormones and antihormones	Therapeutic equivalent to bicalutamide pour Malignant neoplasms of prostate

Prednisolone

Section	Indications
Hormones and antihormones ◦ Oral > Liquid: 5 mg per mL ◦ Oral > Solid: 5 mg; 25 mg	Lymphoid leukaemia, not elsewhere classified Diffuse large B-cell lymphoma, not otherwise specified Chronic lymphocytic leukaemia or small lymphocytic lymphoma Plasma cell myeloma Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis Unspecified malignant neoplasms of unspecified sites Hodgkin lymphoma Malignant neoplasms of prostate Follicular lymphoma

Prednisone

Section	Indications
Hormones and antihormones	Therapeutic equivalent to prednisolone pour Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone pour Diffuse large B-cell lymphoma, not otherwise specified Therapeutic equivalent to prednisolone pour Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone pour Plasma cell myeloma Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone pour Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone pour Langerhans cell histiocytosis Therapeutic equivalent to prednisolone pour Hodgkin lymphoma Therapeutic equivalent to prednisolone pour Malignant neoplasms of prostate Therapeutic equivalent to prednisolone pour Follicular lymphoma

Tamoxifen

Section	Indications
Hormones and antihormones ◦ Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)	Malignant neoplasms of breast Other specified malignant neoplasms of breast

Triptorelin

Section	Indications
Hormones and antihormones	Therapeutic equivalent to leuprorelin pour Malignant neoplasms of breast Therapeutic equivalent to leuprorelin pour Malignant neoplasms of prostate